# Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

> **NIH NIH UM1** · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2024 · $2,801,829

## Abstract

Abstract
Older persons with HIV (PWH) experience high rates of non-infectious, aging-related
comorbidities including frailty, diabetes (DM), and cardiovascular disease (CVD) compared to the
general population. Geroscience approaches focus on therapeutically targeting fundamental
aging processes to delay onset of or alleviate aging-related comorbidities. Cellular senescence is
a fundamental aging process for which targeted compounds have recently been identified. This
process is characterized by stable growth arrest and chronic inflammation, measurable markers
of which are known as the Senescence-Associated Secretory Phenotype (SASP). Senescent cell
burden and SASP-related factors have been associated with frailty, diabetes, and cardiovascular
disease in persons without HIV. Compared to tissue markers of cellular senescence, soluble
SASP biomarkers are easier to obtain, allowing their application more diverse clinical settings
However, associations between soluble SASP biomarkers and frailty, DM, and CVD have not
been well-characterized among PWH. The proposed study will examine the longitudinal
associations between levels of soluble SASP biomarkers and frailty, CM, and CVD in older PWH
in the AIDS Clinical Trial Group (ACTG) A5322/ HIV Infection, Aging, and Immune Function Long-
term Observational Study (HAILO). This study will extend the work of our currently funded cross-
sectional analysis of SASP biomarkers and frailty, DM, and CVD among HAILO participants and
be the first to characterize the longitudinal associations between SASP biomarkers and these
conditions of interest among PWH. The findings from this study will provide pilot data for potential
biomarkers to be targeted in future interventional trials using senotherapeutic agents to prevent
or alleviate frailty, DM, or CVD among older PWH.

## Key facts

- **NIH application ID:** 11043956
- **Project number:** 3UM1AI068636-18S4
- **Recipient organization:** UNIVERSITY OF CALIFORNIA LOS ANGELES
- **Principal Investigator:** Judith S. Currier
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $2,801,829
- **Award type:** 3
- **Project period:** 2006-06-29 → 2027-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11043956

## Citation

> US National Institutes of Health, RePORTER application 11043956, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (3UM1AI068636-18S4). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/11043956. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*